[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @ResearchPulse1 ResearchPulse ResearchPulse posts on X about $nvo, $vktx, $lly, reduce the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXXX engagements in the last XX hours. ### Engagements: XXXXXX [#](/creator/twitter::1797282650668797953/interactions)  - X Week XXXXXX -XX% - X Month XXXXXXX +110% - X Months XXXXXXXXX +268% - X Year XXXXXXXXX +520% ### Mentions: XX [#](/creator/twitter::1797282650668797953/posts_active)  - X Week XX -XX% - X Month XXX +5.40% - X Months XXX +140% - X Year XXXXX +234% ### Followers: XXXXX [#](/creator/twitter::1797282650668797953/followers)  - X Week XXXXX +1.60% - X Month XXXXX +21% - X Months XXXXX +103% - X Year XXXXX +405% ### CreatorRank: XXXXXXX [#](/creator/twitter::1797282650668797953/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [countries](/list/countries) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [$nvo](/topic/$nvo) #8, [$vktx](/topic/$vktx) #4, [$lly](/topic/$lly) #80, [reduce](/topic/reduce) 4.44%, [guess](/topic/guess) 4.44%, [$zeal](/topic/$zeal) 4.44%, [$gubra](/topic/$gubra) #2, [$asnd](/topic/$asnd) 2.22%, [$camx](/topic/$camx) 2.22%, [$mtsr](/topic/$mtsr) XXXX% **Top accounts mentioned or mentioned by** [@rn_flex](/creator/undefined) [@rnflex](/creator/undefined) [@jcannush](/creator/undefined) [@nuguntwewt](/creator/undefined) [@pharmdca](/creator/undefined) [@bioinvestor24](/creator/undefined) [@manonthepen](/creator/undefined) [@hatedmoats](/creator/undefined) [@investseekers](/creator/undefined) [@pjamess69](/creator/undefined) [@alphaenu](/creator/undefined) [@kelseyhard10948](/creator/undefined) [@gilamonstrum](/creator/undefined) [@houndcl](/creator/undefined) [@yokisgn](/creator/undefined) [@therealharith](/creator/undefined) [@duartesatirico](/creator/undefined) [@matthew_abcd](/creator/undefined) [@subtleinduction](/creator/undefined) [@lindendoss](/creator/undefined) **Top assets mentioned** [Novo-Nordisk (NVO)](/topic/$nvo) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Eli Lilly and Company (LLY)](/topic/$lly) [Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr) ### Top Social Posts Top posts by engagements in the last XX hours "9.3% WL with once monthly Wegovy. This is interesting since $NVO shortly will start P1 with once monthly semaglutide/wegovy. NVO will use $ASND technology that is expected to reduce side effects vs ordinary Wegovy. That makes it possible to either dose higher with higher WL or go for less side effects $LLY $VKTX" [X Link](https://x.com/ResearchPulse1/status/1987801386596094099) 2025-11-10T08:35Z 1987 followers, 4389 engagements "@Pharmdca If FTC said NO to $NVO buying $MTSR I guess the answer would be the same with $VKTX But neither NVO or other would pay +$10B upfront. Both to high premium and to much risk upfront. Then a licens deal seems more the way forward" [X Link](https://x.com/ResearchPulse1/status/1996330304475472004) 2025-12-03T21:26Z 1987 followers, 1080 engagements "@therealharith Cost is number one reason for stopping GLP1 treatment. So this should improve from now with the lower cash prices. And even better when introduced in Medicare with only $XX as out of pocket pay" [X Link](https://x.com/ResearchPulse1/status/1996522487946027476) 2025-12-04T10:10Z 1987 followers, XXX engagements "@rn_flex @JCanNuSH A bit strange that BP trends upwards after the first 24w 🤔" [X Link](https://x.com/ResearchPulse1/status/1997348127402008933) 2025-12-06T16:51Z 1988 followers, XX engagements "The biggest difference was that there was HUGE expectation for 2735 and it was labelled as placebo like safety. So when the data arrived and there was much more side effects than anticipated yes then it got beaten. $GCPR the opposite. More or less all excepted WL data below Orforglipron or at best equivalent. So seeing the data then it was clearly better than what most of us thought. So one company disappointed and the other outdid expectations and movement in SP accordingly" [X Link](https://x.com/ResearchPulse1/status/1998092399952728229) 2025-12-08T18:08Z 2031 followers, 6365 engagements "While last Fridays GLP1 IQVIA data was impacted by Thanksgiving holiday and therefore is not directly comparable with the week before that then there were some interesting moments. Zepbound scripts declined XXXX% while Wegovy was down XXXX% w/w. Likewise Ozempic scripts fell XXXX% and Mounjaro was down XXXX% As mentioned its difficult to make firm conclusions with the holiday data in mind. But its interesting that Ozempic and Mounjaro dropped more or less the same while the difference was almost X percentage points between Zepbound and Wegovy. Although I dont think we can directly translate" [X Link](https://x.com/ResearchPulse1/status/1998106192237736356) 2025-12-08T19:03Z 2031 followers, 7775 engagements "Korean Celltrion will develop new quadruple agonist oral obesity with target weight loss above 25%. I have never heard of this company before. And this program is still very early. It will start preclinical IND studies next year. They dont yet want to tell which X targets the go for. One thing they mention I find interesting. They believe their molecule can reduce the non responder rate significantly. To below X% Non responder is defined by losing less than X% in XX months. Wegovy has 10-17% non responder through different trials. Tirzepatide has shown 10-30% non responder rate through the 10" [X Link](https://x.com/ResearchPulse1/status/1991083375059157155) 2025-11-19T09:57Z 1987 followers, 1025 engagements "Alzheimer was a long shot with potential X years headstart at all other GLP1. But nonetheless a long shot. The real journey has only just begun $LLY $NVO $VKTX $ZEAL" [X Link](https://x.com/ResearchPulse1/status/1993049546751201586) 2025-11-24T20:10Z 1989 followers, 11.5K engagements "Eloralintide is the ONLY amylin yet without titration. And even those side effects beats any GLP1 In general we have seen very low side effects in more or less all amylin so fare You kept saying no Amylin will go beyond 12%. But most if not all from this next generation will. Its only Cagrilintide that has a limited about 12/13%. Eloralintide nn1213 (only test molecule) and one more $NVO (maybe NN355) is selective for Amylin. The other are either equally potent or more potent at calcitonin over Amylin. Amylin will take a significant share of overall obesity meds. Due to the combination of" [X Link](https://x.com/ResearchPulse1/status/1997424641741091069) 2025-12-06T21:55Z 2011 followers, XXX engagements "@rn_flex @ManOnThePen I agree. It can become very expensive to start P3 with suboptimal dosing schemes. $NVO got FDA nod to go straight into P3 in obesity. But they still waited to see data from the big P2b in T2D. That trial had a completely other titration scheme" [X Link](https://x.com/ResearchPulse1/status/1997426198465347861) 2025-12-06T22:01Z 2013 followers, XXX engagements "@investseekers That deal is from last year" [X Link](https://x.com/ResearchPulse1/status/1992206801551438222) 2025-11-22T12:21Z 2017 followers, XXX engagements "@bioinvestor24 @rn_flex @DuarteSatirico Vk2735 30mg oral will at best reach level of Orforglipron" [X Link](https://x.com/ResearchPulse1/status/1994802762903613473) 2025-11-29T16:16Z 2031 followers, XXX engagements "This is why we need to see gender split in obesity trials before we conclude if data is good or bad. The huge WL difference between men and women. We have seen this in multiple different trials/molecules. $LLY $NVO $VKTX" [X Link](https://x.com/ResearchPulse1/status/1996237683333460025) 2025-12-03T15:18Z 2029 followers, 5201 engagements "Important nuances thats often left out of articles. Either bc lack of understanding or purposely for click baiting. $LLY $NVO $VKTX" [X Link](https://x.com/ResearchPulse1/status/1997735943978287318) 2025-12-07T18:32Z 2030 followers, 3053 engagements "Boehringer Ingleheim advance first in class tripple agonist to P2 in obesity. Its a GLP1/GIP/NPY2. So will be very interesting to see data. But since BI is an unlisted BP I guess we will not get any more details This is $GUBRA molecule and their X obesity molecule in development. The most know of course is their Amylin. $GUBRA has X obesity programs with BI and this is the second in trials. GUBRA will in Q1 get their 4th obesity molecule UCN2 in P1. Thats still XXX% owned by GUBRA self. $LLY $NVO $VKTX" [X Link](https://x.com/ResearchPulse1/status/1997937247765590228) 2025-12-08T07:52Z 2031 followers, 1177 engagements "Their margin on GLP1 is much higher Which is better. Get beaten and barely sell anything (9% market share) or +100% growth at XX% reduced price. Thats an easy call. And since Wegovy wasnt launched before July and Ozempic still not launched then NVO will actually get a net boost going in to next year. But as I said it means very little before the sales numbers near million in India" [X Link](https://x.com/ResearchPulse1/status/1998144540138484108) 2025-12-08T21:35Z 2031 followers, XX engagements "Since $NVO has a new ceo anything is possible. I know NVO earlier commented about a year ago that they had looked at all small molecule GLP1 and non of them lived up to what they wanted to see. And since then they have made R&D deals with biotechs to develop new small molecule GLP1. For instance the deal with $SEPN. But yesterdays data from GPCR definitely put them back on the list. Those data looked good and interesting $VKTX. When FTC blocked the deal with $MTSR then I cant see how that should be any different with $VKTX. Its peptide GLP1. Besides that it doesnt look like VKTX is interested" [X Link](https://x.com/ResearchPulse1/status/1998320802526105720) 2025-12-09T09:16Z 2031 followers, 4628 engagements "7.2 is also important. But Wegovy pill is more important $NVO has on purpose delayed filing of CagriSema to make sure the supply chain is robust enough to launch. So they file when they know XX more months is sufficient to build stock. If they sought their stock would be large enough in June 2026 then they would have filed X months ago. Its the same with Wegovy pill. Thats also delayed and no vaucher because they needed this time to build up stock thats big enough to not repeat the Wegovy launch" [X Link](https://x.com/ResearchPulse1/status/1998401948672807142) 2025-12-09T14:38Z 2031 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ResearchPulse1 ResearchPulse
ResearchPulse posts on X about $nvo, $vktx, $lly, reduce the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXXX engagements in the last XX hours.
Engagements: XXXXXX #
- X Week XXXXXX -XX%
- X Month XXXXXXX +110%
- X Months XXXXXXXXX +268%
- X Year XXXXXXXXX +520%
Mentions: XX #
- X Week XX -XX%
- X Month XXX +5.40%
- X Months XXX +140%
- X Year XXXXX +234%
Followers: XXXXX #
- X Week XXXXX +1.60%
- X Month XXXXX +21%
- X Months XXXXX +103%
- X Year XXXXX +405%
CreatorRank: XXXXXXX #
Social Influence
Social category influence stocks XXXXX% countries XXXX% finance XXXX%
Social topic influence $nvo #8, $vktx #4, $lly #80, reduce 4.44%, guess 4.44%, $zeal 4.44%, $gubra #2, $asnd 2.22%, $camx 2.22%, $mtsr XXXX%
Top accounts mentioned or mentioned by @rn_flex @rnflex @jcannush @nuguntwewt @pharmdca @bioinvestor24 @manonthepen @hatedmoats @investseekers @pjamess69 @alphaenu @kelseyhard10948 @gilamonstrum @houndcl @yokisgn @therealharith @duartesatirico @matthew_abcd @subtleinduction @lindendoss
Top assets mentioned Novo-Nordisk (NVO) Viking Therapeutics, Inc (VKTX) Eli Lilly and Company (LLY) Metsera, Inc. Common Stock (MTSR)
Top Social Posts
Top posts by engagements in the last XX hours
"9.3% WL with once monthly Wegovy. This is interesting since $NVO shortly will start P1 with once monthly semaglutide/wegovy. NVO will use $ASND technology that is expected to reduce side effects vs ordinary Wegovy. That makes it possible to either dose higher with higher WL or go for less side effects $LLY $VKTX"
X Link 2025-11-10T08:35Z 1987 followers, 4389 engagements
"@Pharmdca If FTC said NO to $NVO buying $MTSR I guess the answer would be the same with $VKTX But neither NVO or other would pay +$10B upfront. Both to high premium and to much risk upfront. Then a licens deal seems more the way forward"
X Link 2025-12-03T21:26Z 1987 followers, 1080 engagements
"@therealharith Cost is number one reason for stopping GLP1 treatment. So this should improve from now with the lower cash prices. And even better when introduced in Medicare with only $XX as out of pocket pay"
X Link 2025-12-04T10:10Z 1987 followers, XXX engagements
"@rn_flex @JCanNuSH A bit strange that BP trends upwards after the first 24w 🤔"
X Link 2025-12-06T16:51Z 1988 followers, XX engagements
"The biggest difference was that there was HUGE expectation for 2735 and it was labelled as placebo like safety. So when the data arrived and there was much more side effects than anticipated yes then it got beaten. $GCPR the opposite. More or less all excepted WL data below Orforglipron or at best equivalent. So seeing the data then it was clearly better than what most of us thought. So one company disappointed and the other outdid expectations and movement in SP accordingly"
X Link 2025-12-08T18:08Z 2031 followers, 6365 engagements
"While last Fridays GLP1 IQVIA data was impacted by Thanksgiving holiday and therefore is not directly comparable with the week before that then there were some interesting moments. Zepbound scripts declined XXXX% while Wegovy was down XXXX% w/w. Likewise Ozempic scripts fell XXXX% and Mounjaro was down XXXX% As mentioned its difficult to make firm conclusions with the holiday data in mind. But its interesting that Ozempic and Mounjaro dropped more or less the same while the difference was almost X percentage points between Zepbound and Wegovy. Although I dont think we can directly translate"
X Link 2025-12-08T19:03Z 2031 followers, 7775 engagements
"Korean Celltrion will develop new quadruple agonist oral obesity with target weight loss above 25%. I have never heard of this company before. And this program is still very early. It will start preclinical IND studies next year. They dont yet want to tell which X targets the go for. One thing they mention I find interesting. They believe their molecule can reduce the non responder rate significantly. To below X% Non responder is defined by losing less than X% in XX months. Wegovy has 10-17% non responder through different trials. Tirzepatide has shown 10-30% non responder rate through the 10"
X Link 2025-11-19T09:57Z 1987 followers, 1025 engagements
"Alzheimer was a long shot with potential X years headstart at all other GLP1. But nonetheless a long shot. The real journey has only just begun $LLY $NVO $VKTX $ZEAL"
X Link 2025-11-24T20:10Z 1989 followers, 11.5K engagements
"Eloralintide is the ONLY amylin yet without titration. And even those side effects beats any GLP1 In general we have seen very low side effects in more or less all amylin so fare You kept saying no Amylin will go beyond 12%. But most if not all from this next generation will. Its only Cagrilintide that has a limited about 12/13%. Eloralintide nn1213 (only test molecule) and one more $NVO (maybe NN355) is selective for Amylin. The other are either equally potent or more potent at calcitonin over Amylin. Amylin will take a significant share of overall obesity meds. Due to the combination of"
X Link 2025-12-06T21:55Z 2011 followers, XXX engagements
"@rn_flex @ManOnThePen I agree. It can become very expensive to start P3 with suboptimal dosing schemes. $NVO got FDA nod to go straight into P3 in obesity. But they still waited to see data from the big P2b in T2D. That trial had a completely other titration scheme"
X Link 2025-12-06T22:01Z 2013 followers, XXX engagements
"@investseekers That deal is from last year"
X Link 2025-11-22T12:21Z 2017 followers, XXX engagements
"@bioinvestor24 @rn_flex @DuarteSatirico Vk2735 30mg oral will at best reach level of Orforglipron"
X Link 2025-11-29T16:16Z 2031 followers, XXX engagements
"This is why we need to see gender split in obesity trials before we conclude if data is good or bad. The huge WL difference between men and women. We have seen this in multiple different trials/molecules. $LLY $NVO $VKTX"
X Link 2025-12-03T15:18Z 2029 followers, 5201 engagements
"Important nuances thats often left out of articles. Either bc lack of understanding or purposely for click baiting. $LLY $NVO $VKTX"
X Link 2025-12-07T18:32Z 2030 followers, 3053 engagements
"Boehringer Ingleheim advance first in class tripple agonist to P2 in obesity. Its a GLP1/GIP/NPY2. So will be very interesting to see data. But since BI is an unlisted BP I guess we will not get any more details This is $GUBRA molecule and their X obesity molecule in development. The most know of course is their Amylin. $GUBRA has X obesity programs with BI and this is the second in trials. GUBRA will in Q1 get their 4th obesity molecule UCN2 in P1. Thats still XXX% owned by GUBRA self. $LLY $NVO $VKTX"
X Link 2025-12-08T07:52Z 2031 followers, 1177 engagements
"Their margin on GLP1 is much higher Which is better. Get beaten and barely sell anything (9% market share) or +100% growth at XX% reduced price. Thats an easy call. And since Wegovy wasnt launched before July and Ozempic still not launched then NVO will actually get a net boost going in to next year. But as I said it means very little before the sales numbers near million in India"
X Link 2025-12-08T21:35Z 2031 followers, XX engagements
"Since $NVO has a new ceo anything is possible. I know NVO earlier commented about a year ago that they had looked at all small molecule GLP1 and non of them lived up to what they wanted to see. And since then they have made R&D deals with biotechs to develop new small molecule GLP1. For instance the deal with $SEPN. But yesterdays data from GPCR definitely put them back on the list. Those data looked good and interesting $VKTX. When FTC blocked the deal with $MTSR then I cant see how that should be any different with $VKTX. Its peptide GLP1. Besides that it doesnt look like VKTX is interested"
X Link 2025-12-09T09:16Z 2031 followers, 4628 engagements
"7.2 is also important. But Wegovy pill is more important $NVO has on purpose delayed filing of CagriSema to make sure the supply chain is robust enough to launch. So they file when they know XX more months is sufficient to build stock. If they sought their stock would be large enough in June 2026 then they would have filed X months ago. Its the same with Wegovy pill. Thats also delayed and no vaucher because they needed this time to build up stock thats big enough to not repeat the Wegovy launch"
X Link 2025-12-09T14:38Z 2031 followers, XXX engagements